跳至主要内容
临床试验/NCT04054115
NCT04054115终止1 期

The Acute Effects of the Prostaglandin (Alprostadil) on Cerebral and Pulmonary Flow After the Bidirectional Cavopulmonary Connection

The Hospital for Sick Children1 个研究点 分布在 1 个国家目标入组 10 人开始时间: 2019年7月23日最近更新:
适应症
干预措施

试验速览

阶段
1 期
状态
终止
入组人数
10
试验地点
1
主要终点
Cerebral blood flow

研究概览

简要总结

The second stage operation towards single ventricle palliation is 'bidirectional cavopulmonary connection' (BCPC). The superior vena cava is connected to the pulmonary artery, diverting 'blue' blood from the upper body (including the brain) to the lungs. A successful BCPC requires sufficient and easy blood flow through the lungs. Alprostadil is the synthetic form of prostaglandin (hormone that causes dilation of blood vessels) and has been shown to increase blood flow in the brain hence increasing blood flow to the lungs after BCPC, potentially useful in managing children post BCPC with low flow to the lungs and thus poor oxygenation. This study propose to investigate acute effects of Alprostadil on different blood vessels after BCPC.

研究设计

研究类型
Interventional
分配方式
Na
干预模型
Single Group
主要目的
Treatment
盲法
None

入排标准

年龄范围
1 Year 至 6 Years(Child)
性别
All
接受健康志愿者

入选标准

  • BCPC patients at time of routine pre-Fontan assessment: Cardiac catheterization and cardiac magnetic resonance imaging (CMR)
  • Patients between the ages of 1 and 6 years old.

排除标准

  • Patients who are hypersensitive to this product or to any ingredient in its formulation.
  • Patients with seizure disorders or coagulopathies.
  • Patients with abnormal kidney function.

研究组 & 干预措施

Treatment Arm

Experimental
  1. Baseline cardiac catheterization under GA. (Standard of Care, SOC)

  2. Transfer patient to MRI unit

  3. Baseline MRI

  4. Obtain ABG for pCO2 from existing femoral arterial access.

  5. Repeat pressure measurements with existing catheters at the SVC, RA and Aorta.

  6. MRI phase contrast imaging for flow measurements(SOC).

  7. During the MRI, Alprostadil infusion will be started and titrated to the target dose 0.1mcg/kg/min, provided there is a less than 20% drop in blood pressure from baseline.

  8. Post alprostadil infusion

  9. 1ml blood sample taken from existing femoral venous access for prostaglandin level.

  10. Repeat pressure measurements with existing catheters left at the SVC, RA and Aorta.

  11. Repeat MRI flow measurements

7.Return to cath lab if further intervention required. 8.Recovery and monitoring for 4 to 6 hours prior to discharge(SOC).

干预措施: Alprostadil 5 MCG Injection (Drug)

结局指标

主要结局

Cerebral blood flow

时间窗: will be measured 30 minutes to 40 minutes after infusion of alprostadil

Cerebral blood flow

次要结局

未报告次要终点

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Rajiv Chaturvedi

Staff Cardiologist

The Hospital for Sick Children

研究点 (1)

Loading locations...

相似试验